Vicki Wheelock MD HDSA Center of Excellence at UC Davis ...

More documents

Recommendations

Info

CREST-E study • Sponsor: NIH, Phase III • Drug: Creatine 5 to 40 gm/day* • Trial type: Double-blind, randomized, placebo controlled • Previous trials: Creatine in HD • Primary endpoint: slowing in rate of progression of HD H · S · G Huntington · Study · Group *Must have medical supervision at high doses to avoid toxicity.
PREQUEL: coming soon • Sponsor: NIH • Drug: Coenzyme Q10 • Participants: 110 people with the HD CAG expansion with no motor findings of HD • Design: all groups on active treatment – 600, 1200, 2400 mg CoQ10 • Planned launch: summer 2009 H · S · G Huntington · Study · Group
Page 1 and 2: Vicki Wheelock MD HDSA Center of Ex
Page 3 and 4: Presenter Disclosures Dr. Vicki Whe
Page 5 and 6: Clinical research studies, especial
Page 7 and 8: The pathway to finding new drugs Pr
Page 9 and 10: What are double blind, randomized,
Page 11 and 12: Who can participate in clinical tri
Page 13 and 14: How much time is required? • Stud
Page 15 and 16: What kinds of activities take place
Page 17 and 18: What kinds of activities take place
Page 19 and 20: What about privacy? • Confidentia
Page 21 and 22: Current observational studies Study
Page 23 and 24: The HD Pipeline Source: Marsha Mill
Page 25 and 26: Results: Tetrabenazine H · S · G
Page 27 and 28: Getting involved in research: Five
Page 29 and 30: There are reasons for and against v
Page 31 and 32: COHORT COHORT • Cooperative Hunti
Page 33 and 34: • Sponsor: NIH PREDICT study •
Page 36 and 37: 2CARE Study • Sponsor: NIH, Phase
Page 38 and 39: HART trial • Sponsor: Neurosearch
Page 42: H · S · G Huntington · Study ·

Vicki Wheelock MD HDSA Center of Excellence at UC Davis ...

Create successful ePaper yourself

Delete template?

Save as template?